- Home
- PLRX vs CGTX Comparison
PLRX vs CGTX Comparison
Compare PLRX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | CGTX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 94.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLRX | CGTX |
|---|---|---|
| Price | $1.39 | $1.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $3.75 | $3.33 |
| AVG Volume (30 Days) | 621.1K | ★ 637.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $0.22 |
| 52 Week High | $1.95 | $3.83 |
Technical Indicators
Market Signals| Indicator | PLRX | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 50.69 |
| Support Level | $1.12 | $1.00 |
| Resistance Level | $1.43 | $1.19 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 94.59 | 72.17 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.